Fredun Pharmaceuticals' board has recommended a 2:1 bonus issue, granting two new equity shares for every one held. According to reports from The Economic Times, the decision was made in a board meeting held on Monday, May 25, 2026, with the bonus issue payment subject to shareholders' approval. The company will pay two fully paid-up equity shares of ₹10 each for every 1 existing equity share of ₹10 each to eligible shareholders and warrant holders as on the record date. As reported by PNN, this move reflects Fredun's strategic intent to strengthen its position across multiple high-growth segments and aligns with the company's consistent value creation philosophy while reinforcing commitment to delivering long-term, inclusive wealth creation for shareholders.
In FY26, Fredun reported total revenues of ₹639.12 crore, with an Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) of ₹94.79 crore and a profit after tax (PAT) of ₹33.21 crore. The company's annual revenue growth of 40.08% significantly outperformed its 3-year CAGR of 31.85%, demonstrating strong momentum in its business operations. As reported by The Economic Times, the board meeting on May 25, 2026, approved the audited financial results for Q4 and FY26. The company's strong financial performance has provided the foundation for the bonus issue recommendation, with robust performance across revenue and profitability metrics. The inauguration of its 5th GMP-certified manufacturing facility in April 2026 provides significant capacity headroom to support scaling across all verticals.
Fredun Pharma shares are currently trading at ₹2,397.80 as of May 26, 2026, representing a 0.57% increase from the previous close of ₹2,384.10. The stock has demonstrated strong performance over the past year, with a 52-week high of ₹2,620.00 and a 52-week low of ₹690.00, indicating significant volatility. The company's market capitalization stands at ₹1,135.23 crore, positioning it as a small-cap pharmaceutical company. According to market data, the stock shows a PE ratio of 43.84 and a PB ratio of 8.68, reflecting the company's growth trajectory and market positioning.
According to the company's filing to exchanges, Fredun operates across multiple high-growth segments including branded generic exports to 52 countries, domestic Fredun Gx formulations, an integrated pet healthcare platform (Freossi, Wagr and One Pet Stop), nutraceuticals, cosmeceuticals (Bird N Beauty), and mobility products. The company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries, and Latin America. As reported by PNN, Fredun offers a diverse range of products including antihypertensives, antidiabetics, antiretroviral drugs (ARVs), and narcotics, along with dietary/herbal supplements, nutraceuticals, cosmeceuticals, and animal healthcare products. With such a comprehensive portfolio, the company's objective is to be a holistic healthcare provider across various therapeutic areas.
Managing Director Fredun Medhora commented on the development, stating that the 2:1 bonus issue reflects strong momentum and confidence in sustaining growth trajectory. According to The Economic Times, Medhora emphasized the company's robust performance across revenue and profitability, continued progress in diversifying into higher-value segments such as nutraceuticals, cosmeceuticals and pet healthcare, and strengthening the quality and scalability of the business. As reported by PNN, the bonus issue represents a way of sharing progress with shareholders while reinforcing commitment to consistent, long-term value creation and inclusive wealth creation for shareholders. The recommendation underscores the company's strong momentum and confidence in sustaining this growth trajectory across its diversified pharmaceutical and healthcare portfolio.
